Remedy: Discounted premium growth - Redeye

Redeye lowers its expectations and valuation on Remedy. However, we expect a steady build-up period will be initiated at the beginning of 2023 when game projects move into the next phase of development. The Remedy stock is traded at half its value since our research update in April where we lowered our estimates and valuation. As in our initial coverage report in late 2018, we yet again state that Remedy offers investors “Premium at a discount”.

Länk till analysen i sin helhet: https://www.redeye.se/research/853851/remedy-discounted-premium-growth?utm_source=finwire&utm_medium=RSS